News & Updation
Best Paper Awards
World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.
Best Article of current issue
Download Article : Click here
TRANEXAMIC ACID FOR THE PREVENTION OF BLOOD LOSS AFTER CESAREAN DELIVERY
*Dr. Ghadah Salah Abdulrazzaq and Dr. Yusra Yousif Najm
Background: Postpartum hemorrhage, a major maternal fatality, is linked to advanced age, nuliparity, uterinefibroids, and labor characteristics. Tranexamic acid, a fibrinolysis inhibitor, may reduce mortality. Aim of thestudy: To assess the effectiveness of Tranexamic acid in the prevention of postpartum hemorrhage following thedelivery by cesarean section. Methodology: A randomized-controlled clinical trial was carried out for 360 womenwho were at risk of postpartum hemorrhage at Al-SalamTeaching Hospital between February 1, 2020, andDecember 1, 2021. The participants were divided into two groups: those who received Tranexamic acid beforecesarean incision and those who received normal saline solution. Oxytocin was administered after delivery. Allpatients were assessed by full history, clinical examination, and laboratory investigations. The study used SPSS-26 for statistical analysis, with a chi-square for proportions and a t-test for unpaired data. The p-value of ≤0.05was considered significant. Results: The study found that the mean age of the Tranexamic acid group was 30.34 ±8.3 years, while the control group had a mean age of 29.05 ± 6.9 years. The study also found that 70.0% of theTranexamic acid group had a previous cesarean section, and the average amount of blood loss was significantlyhigher in the Tranexamic acid group (435.67 ± 80.45 cc) compared to the control group (588.23 ± 129.33 cc).Conclusion: Tranexamic acid is a cost-effective and safe medication used to reduce blood loss during CS withoutshort-term negative effects on the mother or fetus.[Full Text Article] [Download Certificate]